Skip to content
Investment Visual

NTRA

Natera, Inc.

$319.09−3.85 (−1.19%)Close Nov 13, 2026

Backtest NTRA

Insider trading

12 months to Nov 10, 2026
Sold
$365M
12 insiders
Largest seller
$135M
Matthew Rabinowitz · 37% of sales
Plan sales
$315M
86% of sales
Latest buy
Mar 16, 2022
Roelof Botha

Buys and sales on the price

Since 2015

By period

Open-market trades
Trades3 months12 monthsSince 2015
Buys007
Sales38170964
Plan sales38164805
Shares bought00002,046,4932.05M
Shares sold289,319289K1,451,8221.45M12,210,86412.2M
Net shares−289,319−289K−1,451,822−1.45M−10,164,371−10.2M
Net value−$104M−$365M−$1.01B

Insiders

Insider12 monthsShares held
Matthew Rabinowitz
Executive Chairman, Director
−16.5%
2,116,928
Roelof Botha
Director
−12.4%
1,080,783
Jonathan Sheena
Director
−37.5%
230,962
John Fesko
President, Chief BUS. Officer
−25.3%
195,276
Daniel Rabinowitz
SEC. and Chief Legal Officer
−48.8%
167,880

Trades

971 trades since 2015
TypeInsiderRoleSharesPriceHeld after
Nov 6, 2026Plan sale
Jonathan SheenaDirector
Director
Director
3,150
at $316.00
$316.00$995K
−1.3%
231K after
230,962
Nov 3, 2026Plan sale
Michael Burkes BrophyChief Financial Officer
Chief Financial Officer
Chief Financial Officer
470
at $391.49
$391.49$184K
−1.0%
45.8K after
45,779
Nov 2, 2026Plan sale
John FeskoPresident, Chief BUS. Officer
President, Chief BUS. Officer
President, Chief BUS. Officer
302
at $400.01
$400.01$121K
−0.2%
195K after
195,276
Nov 2, 2026Plan sale
Solomon MoshkevichPresident, Clinicaldiagnostics
President, Clinicaldiagnostics
President, Clinicaldiagnostics
3,419
at $409.77
$409.77$1.40M
−3.3%
101K after
101,323
Nov 2, 2026Plan sale
Daniel RabinowitzSEC. and Chief Legal Officer
SEC. and Chief Legal Officer
SEC. and Chief Legal Officer
341
at $400.05
$400.05$136K
−0.2%
168K after
167,880
Nov 2, 2026Plan sale
Steven Leonard ChapmanCEO and President, Director
CEO and President, Director
CEO and President, Director
3,801
at $411.80
$411.80$1.57M
−4.2%
87.4K after
87,431
Nov 2, 2026Plan sale
Michael Burkes BrophyChief Financial Officer
Chief Financial Officer
Chief Financial Officer
325
at $399.99
$399.99$130K
−0.7%
46.2K after
46,249
Nov 2, 2026Plan sale
Jonathan SheenaDirector
Director
Director
112
at $399.97
$399.97$44.8K
−<0.1%
234K after
234,074
Nov 2, 2026Plan sale
Matthew RabinowitzExecutive Chairman, Director
Executive Chairman, Director
Executive Chairman, Director
748
at $400.02
$400.02$299K
−<0.1%
2.12M after
2,116,928
Oct 30, 2026Plan sale
Michael Burkes BrophyChief Financial Officer
Chief Financial Officer
Chief Financial Officer
1,906
at $425.55
$425.55$811K
−3.9%
46.6K after
46,574
  • Jonathan Sheena$995K
    Nov 6, 2026 · Plan sale3,150 at $316.00
    Director−1.3% of holdings, 231K after
  • Michael Burkes Brophy$184K
    Nov 3, 2026 · Plan sale470 at $391.49
    Chief Financial Officer−1.0% of holdings, 45.8K after
  • John Fesko$121K
    Nov 2, 2026 · Plan sale302 at $400.01
    President, Chief BUS. Officer−0.2% of holdings, 195K after
  • Solomon Moshkevich$1.40M
    Nov 2, 2026 · Plan sale3,419 at $409.77
    President, Clinicaldiagnostics−3.3% of holdings, 101K after
  • Daniel Rabinowitz$136K
    Nov 2, 2026 · Plan sale341 at $400.05
    SEC. and Chief Legal Officer−0.2% of holdings, 168K after
  • Steven Leonard Chapman$1.57M
    Nov 2, 2026 · Plan sale3,801 at $411.80
    CEO and President, Director−4.2% of holdings, 87.4K after
  • Michael Burkes Brophy$130K
    Nov 2, 2026 · Plan sale325 at $399.99
    Chief Financial Officer−0.7% of holdings, 46.2K after
  • Jonathan Sheena$44.8K
    Nov 2, 2026 · Plan sale112 at $399.97
    Director−<0.1% of holdings, 234K after
  • Matthew Rabinowitz$299K
    Nov 2, 2026 · Plan sale748 at $400.02
    Executive Chairman, Director−<0.1% of holdings, 2.12M after
  • Michael Burkes Brophy$811K
    Oct 30, 2026 · Plan sale1,906 at $425.55
    Chief Financial Officer−3.9% of holdings, 46.6K after